Similar articles for PMID: 26871003

Year	Number of Results
1982	1
1987	4
1990	1
1992	2
1993	1
1994	1
1995	1
1996	3
1997	2
1998	1
1999	7
2000	6
2001	2
2002	2
2003	5
2004	1
2005	5
2006	2
2007	4
2008	3
2009	4
2010	4
2011	4
2012	5
2013	7
2014	3
2015	10
2016	11
2017	7
2018	6
2019	7
2020	7
2021	5
2022	4
2023	1
2024	0

1

Conjugation of 10 kDa Linear PEG onto Trastuzumab Fab' Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity.

Chan LJ, Ascher DB, Yadav R, Bulitta JB, Williams CC, Porter CJ, Landersdorfer CB, Kaminskas LM. Chan LJ, et al. Mol Pharm. 2016 Apr 4;13(4):1229-41. doi: 10.1021/acs.molpharmaceut.5b00749. Epub 2016 Feb 29. Mol Pharm. 2016. PMID: 26871003

2

PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration.

Chan LJ, Bulitta JB, Ascher DB, Haynes JM, McLeod VM, Porter CJ, Williams CC, Kaminskas LM. Chan LJ, et al. Mol Pharm. 2015 Mar 2;12(3):794-809. doi: 10.1021/mp5006189. Epub 2015 Feb 18. Mol Pharm. 2015. PMID: 25644368

3

Comparative binding of disulfide-bridged PEG-Fabs.

Khalili H, Godwin A, Choi JW, Lever R, Brocchini S. Khalili H, et al. Bioconjug Chem. 2012 Nov 21;23(11):2262-77. doi: 10.1021/bc300372r. Epub 2012 Oct 18. Bioconjug Chem. 2012. PMID: 22994419

4

Production of a PEGylated Fab' of the anti-LINGO-1 Li33 antibody and assessment of its biochemical and functional properties in vitro and in a rat model of remyelination.

Pepinsky RB, Walus L, Shao Z, Ji B, Gu S, Sun Y, Wen D, Lee X, Wang Q, Garber E, Mi S. Pepinsky RB, et al. Bioconjug Chem. 2011 Feb 16;22(2):200-10. doi: 10.1021/bc1002746. Epub 2011 Jan 21. Bioconjug Chem. 2011. PMID: 21254764

5

Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.

Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D. Kirpotin D, et al. Biochemistry. 1997 Jan 7;36(1):66-75. doi: 10.1021/bi962148u. Biochemistry. 1997. PMID: 8993319

6

Trastuzumab- and Fab' fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo.

Duan D, Wang A, Ni L, Zhang L, Yan X, Jiang Y, Mu H, Wu Z, Sun K, Li Y. Duan D, et al. Int J Nanomedicine. 2018 Mar 22;13:1831-1840. doi: 10.2147/IJN.S153795. eCollection 2018. Int J Nanomedicine. 2018. PMID: 29606874 Free PMC article.

7

Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering.

Humphreys DP, Heywood SP, Henry A, Ait-Lhadj L, Antoniw P, Palframan R, Greenslade KJ, Carrington B, Reeks DG, Bowering LC, West S, Brand HA. Humphreys DP, et al. Protein Eng Des Sel. 2007 May;20(5):227-34. doi: 10.1093/protein/gzm015. Epub 2007 Apr 23. Protein Eng Des Sel. 2007. PMID: 17452434

8

Site specific discrete PEGylation of (124)I-labeled mCC49 Fab' fragments improves tumor MicroPET/CT imaging in mice.

Ding H, Carlton MM, Povoski SP, Milum K, Kumar K, Kothandaraman S, Hinkle GH, Colcher D, Brody R, Davis PD, Pokora A, Phelps M, Martin EW Jr, Tweedle MF. Ding H, et al. Bioconjug Chem. 2013 Nov 20;24(11):1945-54. doi: 10.1021/bc400375f. Epub 2013 Oct 31. Bioconjug Chem. 2013. PMID: 24175669 Free PMC article.

9

Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation.

Leong SR, DeForge L, Presta L, Gonzalez T, Fan A, Reichert M, Chuntharapai A, Kim KJ, Tumas DB, Lee WP, Gribling P, Snedecor B, Chen H, Hsei V, Schoenhoff M, Hale V, Deveney J, Koumenis I, Shahrokh Z, McKay P, Galan W, Wagner B, Narindray D, Hébert C, Zapata G. Leong SR, et al. Cytokine. 2001 Nov 7;16(3):106-19. doi: 10.1006/cyto.2001.0936. Cytokine. 2001. PMID: 11741351

10

Effect of polyethylene glycol conjugation on conformational and colloidal stability of a monoclonal antibody antigen-binding fragment (Fab').

Roque C, Sheung A, Rahman N, Ausar SF. Roque C, et al. Mol Pharm. 2015 Feb 2;12(2):562-75. doi: 10.1021/mp500658w. Epub 2015 Jan 14. Mol Pharm. 2015. PMID: 25548945

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

130 results

Results by year